Stephen V Liu: Results from phase III CONTACT-01 trial Journal of Clinical Oncology

Stephen V Liu, Director of Thoracic Oncology and Developmental Therapeutics at Lombardi Comprehensive Cancer Center, posted on X:

“Results from phase III CONTACT-01 trial Journal of Clinical Oncology. Randomized 186 pts with NSCLC and prior chemo and immunotherapy to either atezolizumab + cabozantinib or standard docetaxel. Atezo/cabo did not improve OS (10.7m vs 10.5m, HR 0.88, ns) & was more toxic.”